SCHEMBL877953

SCHEMBL877953

COC(=O)C(CCn1nnc2ccccc2c1=O)S(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ALDH1A1 P00352 3/20 0.47
GAA P10253 2/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPK1 P28482 2/20 0.46
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP3 P08254 1/20 0.44
MMP9 P14780 1/20 0.44
MMP13 P45452 1/20 0.44
TP53 P04637 1/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15735071 0.91 ALDH1A1 (0.48) LMNASMN1; SMN2ALDH1A1GAAKMT2A
SCHEMBL878087 0.88 SMN1; SMN2 (0.46) LMNASMN1; SMN2ALDH1A1GAAKMT2A
SCHEMBL878059 0.85 GPR139 (0.46) LMNASMN1; SMN2ALDH1A1GAAKMT2A
SCHEMBL878420 0.84 KMT2A (0.45) LMNASMN1; SMN2ALDH1A1GAAKMT2A
SCHEMBL876948 0.81 MAPK10 (0.43) LMNASMN1; SMN2ALDH1A1GAAKMT2A
SCHEMBL876908 0.80 ALDH1A1 (0.47) LMNASMN1; SMN2ALDH1A1GAAKMT2A
SCHEMBL15735075 0.78 ALDH1A1 (0.47) LMNASMN1; SMN2ALDH1A1GAAKMT2A
SCHEMBL874823 0.78 MMP2 (0.61) ALDH1A1KMT2AMEN1KDM4EMMP1
SCHEMBL877642 0.77 GPR139 (0.48) LMNASMN1; SMN2ALDH1A1GAAKMT2A
SCHEMBL877413 0.76 MMP2 (0.50) ALDH1A1KMT2AMEN1KDM4EMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US disclosed
EP-2619185-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP disclosed
WO-2012038942-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP12, MMP10 LMNA 2726/4885SMN1; SMN2 3367/4885ALDH1A1 2281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.